LUX 3RETA

Retatrutide is an investigational triple receptor agonist studied in metabolic and obesity research. Published literature has explored its effects on body weight, appetite-related pathways, and broader cardiometabolic markers through combined activation of GLP-1, GIP, and glucagon receptors.

What retatrutide has been studied for

• obesity and body-weight reduction
• metabolic regulation
• appetite and energy-balance pathways
• type 2 diabetes research
• cardiometabolic and obesity-related comorbidity research

Relevant study
“Triple–Hormone-Receptor Agonist Retatrutide for Obesity” in The New England Journal of Medicine. In that phase 2 trial, adults with obesity had substantial weight reduction over 48 weeks, including up to 24.2% mean weight loss at the highest dose studied.